NASDAQ:SLDB - Solid Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.70
  • Forecasted Upside: 76.78 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.79
▲ +0.36 (10.50%)
1 month | 3 months | 12 months
Get New Solid Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLDB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLDB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.70
▲ +76.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $6.70, with a high forecast of $12.50 and a low forecast of $2.00. The average price target represents a 76.78% upside from the last price of $3.79.
Buy
The current consensus among 5 investment analysts is to buy stock in Solid Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/5/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
8/3/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 2 sell ratings
11/1/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2020Chardan CapitalBoost Price TargetBuy$5.00 ➝ $12.50High
i
Rating by Gbola Amusa at Chardan Capital
8/14/2020Chardan CapitalReiterated RatingBuy$5.00Medium
i
Rating by Gbola Amusa at Chardan Capital
7/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$3.00High
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/21/2020NomuraReiterated RatingBuy$6.00Low
i
5/9/2020Chardan CapitalReiterated RatingBuy$5.00High
i
Rating by Gbola Amusa at Chardan Capital
5/8/2020NomuraLower Price TargetBuy$10.00 ➝ $6.00Low
i
3/23/2020Chardan CapitalReiterated RatingBuy$6.75 ➝ $5.00High
i
12/18/2019Nomura SecuritiesBoost Price TargetBuy$6.00 ➝ $10.00High
i
11/12/2019Credit Suisse GroupLower Price TargetUnderperform ➝ Hold$6.00 ➝ $2.00High
i
10/11/2019Evercore ISIInitiated CoverageOutperform$22.00High
i
8/29/2019CitigroupDowngradeNeutral ➝ Sell$6.00High
i
Rating by Joel Beatty at Citigroup Inc.
8/19/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$8.00 ➝ $15.00High
i
Rating by J. Schwartz at SVB Leerink LLC
8/16/2019Chardan CapitalUpgradeNeutral ➝ Buy$7.50 ➝ $10.00High
i
Rating by G. Amusa at Chardan Capital
5/16/2019CitigroupSet Price TargetHold$6.00Low
i
Rating by Joel Beatty at Citigroup Inc.
5/14/2019Chardan CapitalDowngradeBuy ➝ Neutral$15.00 ➝ $7.50High
i
Rating by G. Amusa at Chardan Capital
5/14/2019Goldman Sachs GroupDowngradeNeutral ➝ Sell$5.00 ➝ $4.00High
i
5/14/2019Credit Suisse GroupDowngradeNeutral ➝ Underperform$7.00 ➝ $6.00High
i
2/8/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by J. Schwartz at SVB Leerink LLC
2/8/2019CitigroupUpgradeSell ➝ Neutral$8.00Medium
i
2/7/2019Chardan CapitalReiterated RatingBuy$15.00High
i
12/10/2018BTIG ResearchInitiated CoverageNeutralLow
i
12/3/2018CitigroupBoost Price TargetHold ➝ Sell$25.00 ➝ $31.00High
i
11/6/2018CitigroupInitiated CoverageSell$25.00High
i
9/6/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$38.00High
i
6/25/2018Nomura SecuritiesBoost Price TargetBuy$37.00 ➝ $57.00High
i
6/24/2018Chardan CapitalReiterated RatingBuy$60.00Low
i
Rating by G. Amusa at Chardan Capital
6/20/2018SVB LeerinkBoost Price TargetOutperform$28.00 ➝ $50.00High
i
Rating by J. Schwartz at SVB Leerink LLC
5/10/2018Chardan CapitalReiterated RatingBuy$37.50Low
i
Rating by G. Amusa at Chardan Capital
5/10/2018SVB LeerinkBoost Price TargetOutperform$14.00 ➝ $28.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
4/2/2018SVB LeerinkLower Price TargetOutperform ➝ Hold$36.00 ➝ $14.00Medium
i
Rating by J. Schwartz at SVB Leerink LLC
3/19/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$52.00 ➝ $37.00Low
i
3/15/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$28.00High
i
2/21/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$40.00High
i
Rating by G. Amusa at Chardan Capital
2/20/2018Nomura SecuritiesInitiated CoverageBuy ➝ Buy$52.00Medium
i
2/20/2018Nomura InstinetInitiated CoverageBuy$52.00High
i
2/20/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$36.00High
i
Rating by J. Schwartz at SVB Leerink LLC
2/20/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$28.00High
i
2/20/2018Goldman Sachs GroupInitiated CoverageNeutral$31.00High
i
(Data available from 10/26/2015 forward)
Solid Biosciences logo
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $3.79
$3.48
$3.93

50 Day Range

MA: $2.98
$2.02
$4.75

52 Week Range

Now: $3.79
$1.93
$12.84

Volume

13,373,000 shs

Average Volume

1,490,842 shs

Market Capitalization

$174.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09